Fernando C. Santini

1.5k total citations
34 papers, 958 citations indexed

About

Fernando C. Santini is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Fernando C. Santini has authored 34 papers receiving a total of 958 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in Fernando C. Santini's work include Lung Cancer Treatments and Mutations (23 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Research Studies (7 papers). Fernando C. Santini is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Research Studies (7 papers). Fernando C. Santini collaborates with scholars based in United States, Brazil and South Korea. Fernando C. Santini's co-authors include Alexander Drilon, Matthew D. Hellmann, Charles M. Rudin, Ana O. Hoff, Priscilla Cukier, Mariana Scaranti, Mark G. Kris, Jamie E. Chaft, Elizabeth Panora and Olivia Wilkins and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Fernando C. Santini

31 papers receiving 948 citations

Peers

Fernando C. Santini

ONCOL

PRM

IMMUN

Keita Kudo Japan

Jacob Sands United States

Yuichi Sakamori Japan

Erin Larkins United States

Ryoji Kato Japan

Dengfeng Ren China

Santiago Ponce Aix Spain

J.M. Sánchez-Torres Spain

Ivana Sullivan Spain

Sumie Koike Japan

Keita Kudo Japan

Fernando C. Santini

1.0k ×1.5

ONCOL

611 ×1.3

PRM

173 ×0.8

107 ×0.7

193 ×1.7

IMMUN

Citations per year, relative to Fernando C. Santini Fernando C. Santini (= 1×) peers Keita Kudo

Countries citing papers authored by Fernando C. Santini

Since Specialization

Citations

This map shows the geographic impact of Fernando C. Santini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando C. Santini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando C. Santini more than expected).

Fields of papers citing papers by Fernando C. Santini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernando C. Santini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando C. Santini. The network helps show where Fernando C. Santini may publish in the future.

Co-authorship network of co-authors of Fernando C. Santini

This figure shows the co-authorship network connecting the top 25 collaborators of Fernando C. Santini. A scholar is included among the top collaborators of Fernando C. Santini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernando C. Santini. Fernando C. Santini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harada, Guilherme, Fernando C. Santini, Jason C. Chang, et al.. (2025). Final results of a phase II study of cabozantinib in patients with MET -altered lung cancers.. Journal of Clinical Oncology. 43(16_suppl). 8645–8645. 1 indexed citations

Offin, Michael, Daphna Y. Gelblum, Fernando C. Santini, et al.. (2024). Exploratory analysis of CTDNA and imaging response in Phase I/II chorus study of canakinumab with chemoradiation and durvalumab for NSCLC. 5. 100232–100232. 1 indexed citations

Yu, Helena A., Monica F. Chen, Angela Bik‐Yu Hui, et al.. (2024). A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease.. Journal of Clinical Oncology. 42(16_suppl). 8517–8517. 6 indexed citations

Goto, Keiko, Benjamin Solomon, K. Park, et al.. (2023). LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC. Annals of Oncology. 34. S1303–S1303. 4 indexed citations

Thummalapalli, Rohit, Bob T. Li, Afsheen N. Iqbal, et al.. (2023). Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer. JCO Precision Oncology. 7(7). e2300030–e2300030. 23 indexed citations

Macêdo, Mariana Petaccia de, Fernando Augusto Soares, Fernando C. Santini, et al.. (2023). Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors. SHILAP Revista de lepidopterología. 16. 2632010X231197080–2632010X231197080.

Araújo-Filho, José de Arimateia Batista, María Mayoral, Natally Horvat, et al.. (2022). Radiogenomics in personalized management of lung cancer patients: Where are we?. Clinical Imaging. 84. 54–60. 4 indexed citations

Sandoval, Renata Lazari, Cibele Masotti, Mariana Petaccia de Macêdo, et al.. (2021). Identification of theTP53p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome. JCO Global Oncology. 7(7). 1141–1150. 9 indexed citations

Goto, Kōichi, J. Wolf, Yasir Y. Elamin, et al.. (2021). FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).. Journal of Thoracic Oncology. 16(3). S228–S229. 5 indexed citations

10.

Harada, Guilherme, Fernando C. Santini, Clare Wilhelm, & Alexander Drilon. (2021). NTRK fusions in lung cancer: From biology to therapy. Lung Cancer. 161. 108–113. 31 indexed citations

11.

Harada, Guilherme, et al.. (2020). TRK Inhibitors in Non-Small Cell Lung Cancer. Current Treatment Options in Oncology. 21(5). 39–39. 13 indexed citations

12.

Loong, Herbert H., Kōichi Goto, Yasir Y. Elamin, et al.. (2020). 1413TiP LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S893–S893. 2 indexed citations

13.

Solomon, Benjamin, Alexander Drilon, Keunchil Park, et al.. (2020). Phase III Study of Selpercatinib Versus Chemotherapy ± pembrolizumab in Untreated RET Positive Non-Small-Cell Lung Cancer. Future Oncology. 17(7). 763–773. 30 indexed citations

14.

Harada, Guilherme, et al.. (2019). Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure. ecancermedicalscience. 13. 970–970. 3 indexed citations

15.

Santini, Fernando C., Hira Rizvi, Andrew J. Plodkowski, et al.. (2018). Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunology Research. 6(9). 1093–1099. 263 indexed citations

16.

Santini, Fernando C.. (2017). RET-Rearranged Lung Cancer. 13(10). 1 indexed citations

17.

Cukier, Priscilla, Fernando C. Santini, Mariana Scaranti, & Ana O. Hoff. (2017). Endocrine side effects of cancer immunotherapy. Endocrine Related Cancer. 24(12). T331–T347. 126 indexed citations

18.

Sabari, Joshua K., Fernando C. Santini, Alison M. Schram, et al.. (2017). The activity, safety, and evolving role of brigatinib in patients with <em>ALK</em>-rearranged non-small cell lung cancers. OncoTargets and Therapy. Volume 10. 1983–1992. 46 indexed citations

19.

Sabari, Joshua K., Fernando C. Santini, Isabella Bergagnini, et al.. (2017). Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy. Current Oncology Reports. 19(4). 24–24. 30 indexed citations

20.

Iastrebner, Marcelo, Jun Ho Jang, Kihyun Kım, et al.. (2010). Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience. Leukemia & lymphoma. 51(12). 2250–2257. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact